Company Overview and News
Canadian Pacific Railway Ltd. may match or exceed its record 2014 pace of 110,000 crude carloads next year as a pipeline crunch stokes demand for shipping by train, Chief Executive Officer Keith Creel said late Thursday in an interview from Calgary, where the company is based.
CP CVE CP CVE
Canadian Pacific Railway stock (NYSE:CP) was up after the bell as the company reported its latest quarterly earnings results late in the day Thursday, unveiling profit and revenue that was stronger than what analysts were calling for in their consensus estimate.
CP CP TRI
Canadian Pacific Railway Ltd. says it earned the highest adjusted per-share profits and revenues of its 137-year history last quarter, helping the country's second largest railroad to overcome the impact earlier this year from service interruptions tied to labour action.
2018-10-16 seekingalpha - 2
Activism in Canada is largely responsible for transportation constraints such as pipeline bottlenecks, hurting the Canadian economy in ways that Canadians could never imagine.
BTE CVE CRLFF CEI TOT ENB IMO CNI ZPTAF CHAP RRENF SNZYP TDG SN TRP IMO MEG HKRCP BP VET CVE BTE ECR USEG CHPE CP USO IKM CJ GST-A GST-B GST PTOAF WCP SCAZP HUSKF AXAS PTOAD SGY VET SPE TECK HSE AREX TDGCF CP ROSEU REI AMR MEGEF IPCFF TCKRF RRX ROSE PDS PRCYF RZREF HK SPGYF PTORF
Southwest Airlines Co. (LUV - Free Report) has numerous tailwinds surrounding it, despite being burdened by rising costs, especially fuel, and the impact from recent weather-related disruptions. Let’s delve into these factors. Last month, the company provided a bullish outlook pertaining to unit revenues during the third quarter of 2018. It expects a 0.5 to 1 point year-over-year benefit to its unit revenues (RASM) on account of flight cancellations in the wake of the hurricanes.
CP CP GPN CSX
Investors are always looking for stocks that are poised to beat at earnings season and Canadian Pacific Railway Limited (CP - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
J.B. Hunt Transport Services, Inc. (JBHT - Free Report) is scheduled to release third-quarter 2018 results on Oct 16. Last reported quarter, the company delivered a positive earnings surprise of 7%. Apart from the earnings beat, it reported better-than-expected revenues. Moreover, both the metrics improved year over year. Lower effective tax rate aided results. However, things do not look too rosy for the third quarter.
CBSH CP CP CBSHP CHRW ALK CBCB
United Continental Holdings, Inc. (UAL - Free Report) is scheduled to report third-quarter 2018 results on Oct 16, before the market opens. Last reported quarter, the company delivered a positive earnings surprise of 5.2% with better-than-expected earnings and revenues. Both the metrics also improved on a year-over-year basis. This apart, the company has an impressive earnings history, having outperformed the Zacks Consensus Estimate in each of the preceding four quarters, with an average beat of 3.
UAL CP CP CHRW ALK
CSX Corporation (CSX - Free Report) is slated to report third-quarter 2018 earnings on Oct 16, after the market closes. Last reported quarter, the company delivered a positive earnings surprise of 17.4%, with better-than-expected earnings and revenues. Moreover, both the measures improved on a year-over-year basis. Results were driven by a 2% rise in volumes, higher fuel recoveries and strong core pricing gains across all major markets.
CP CP CSX CHRW ALK
(Bloomberg) -- Even before the discount on Canadian crude began a brutal streak of new lows in recent days, a variety of efforts were under way to help alleviate Alberta’s persistent crude-shipping bottlenecks. Here’s a look at the major projects in the works as well as a few longer-term solutions:
ENBBF ENB TRP CP CVE CP CVE EBBNF ENB
Canadian Pacific Railway Limited (CP - Free Report) has provided an update on its upcoming third-quarter financial results (to be released on Oct 18) and full-year outlook. Simultaneously, it has outlined a few of its financial objectives for the period 2018-2020. Bullish Q3 View Third-quarter revenues are anticipated to register an all-time high figure of $1.9 billion, reflecting a 19% increase. Third-quarter 2017 revenues were $1.
CP CP UNP CSX TRN
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:CP / Canadian Pacific Railway on message board site Silicon Investor.